Adjuvant Therapy

Adjuvant therapy is treatment given after the primary treatment, usually surgery, to destroy any cancer cells that may remain, lower the chance the cancer comes back, and improve long-term survival. In mesothelioma and asbestos-related lung cancer, adjuvant therapy most often involves chemotherapy, radiation, immunotherapy, or a combination.

Origin

From the Latin adjuvare, meaning "to help." In modern oncology, the term came into wide use in the 1960s and 1970s as trials began showing that chemotherapy added after breast cancer surgery improved survival, establishing the principle that surgery alone often leaves microscopic disease behind.

Significance in Asbestos Context

After surgery for pleural mesothelioma or asbestos-related lung cancer, microscopic cancer cells almost always remain in nearby tissue, and adjuvant therapy is aimed at those residual cells. For pleural mesothelioma, the most common adjuvant chemotherapy regimen is pemetrexed combined with cisplatin (or carboplatin); adjuvant radiation to the surgical bed is sometimes added, especially after pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP). Immunotherapy combinations such as nivolumab plus ipilimumab are increasingly part of the adjuvant or maintenance setting, and clinical trials are actively refining what works best. The regimen your oncologist recommends will depend on the histologic subtype (epithelioid, sarcomatoid, or biphasic), the stage at surgery, how complete the resection was, and your overall fitness. These treatment details appear throughout your medical record and directly document the severity of your disease, information that matters both for your care and for any claim or trust filing.

Example Sentence

After his pleurectomy/decortication for epithelioid mesothelioma, the oncologist recommended adjuvant therapy with four cycles of pemetrexed and cisplatin to reduce the risk of recurrence.

Related Terms

Neoadjuvant Therapy, Multimodal Therapy, Pemetrexed, Pleurectomy/Decortication (P/D), Extrapleural Pneumonectomy (EPP), Immunotherapy

Notes

• Ask your oncologist specific questions before starting: What regimen do you recommend and why? How many cycles or sessions? What side effects should I expect, and what is the plan to manage them? What does the evidence show for my specific subtype and stage? Are there clinical trials of adjuvant or maintenance therapy I might qualify for?
• Do not confuse adjuvant therapy (after primary treatment) with neoadjuvant therapy (before primary treatment, often to shrink a tumor before surgery). Many mesothelioma plans use one or both. Make sure you understand the sequence your team is proposing.
• Keep copies of every treatment record: infusion dates and doses, radiation treatment plans, pre- and post-treatment imaging, lab results, and any hospitalizations or side-effect records. These document both the medical necessity and the cost of your care, which matter for compensation calculations.
• If your oncologist recommends against adjuvant therapy because of your overall health, stage, or surgical findings, ask for that reasoning in writing. Choosing not to pursue adjuvant therapy does not weaken a legal claim. It reflects your individual medical situation.
• Adjuvant therapy applies to malignant asbestos-related diseases (mesothelioma, lung cancer). It is not used for non-malignant conditions such as asbestosis, pleural plaques, or diffuse pleural thickening.